Corbus Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFß blocking monoclonal antibody targeting the integrin avß8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.35 USD | +1.93% |
|
+1.23% | +634.27% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+634.27% | 47Cr | |
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+25.33% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-15.94% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)